Navigation Links
Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
Date:4/14/2008

Nonclinical Studies Demonstrate that SNS-595 Acts through a Dual Mechanism

and May Evade Common Drug Resistance Mechanisms

Research Supports Current Clinical Development of SNS-595 in AML and

Ovarian Cancer and Potential in Additional Indications

SOUTH SAN FRANCISCO, Calif., April 14 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today presented nonclinical data on SNS-595's unique mechanism of action and its anticancer activity at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, CA. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b clinical trial of SNS-595 in combination with cytarabine in relapsed/refractory acute myeloid leukemia (AML) are both ongoing.

"Data presented today provide important new insights into SNS-595's mechanism as a site-selective DNA intercalator and topoisomerase poison with selectivity for proliferating cells. Through its unique chemical structure and molecular mechanism, SNS-595 avoids common drug resistance pathways and may have advantages over other topoisomerase poisons," said Daniel C. Adelman, M.D., Senior Vice President, Development and Chief Medical Officer. "Taken together, these data support our ongoing clinical trials of SNS-595 in platinum-resistant ovarian cancer and acute myeloid leukemia, and provide compelling evidence for future studies of SNS-595 in indications such as breast cancer where topoisomerase II poisons are active."

Sunesis researchers conducted in vitro and cell-based studies elucidating SNS-595's mechanism of action. SNS-595 selectively intercalates DNA and poisons topoisomerase II, resulting in replication-dependent DNA damage, irreversi
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
2. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
3. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
4. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
5. Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast
6. Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
7. ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM)
8. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
9. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
10. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
11. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... Health Organization recommends that youth participate in a minimum ... (MVPA) each day. Studies have shown that youth ... Therefore, it stands to reason that increasing outdoor time ... new study scheduled for publication in The Journal ... after school was positively associated with MVPA. , Drs. ...
(Date:7/9/2014)... (PHILADELPHIA) Researchers at the Perelman School of Medicine ... Roswell Park Cancer Institute have received an $8 million ... the effects of photodynamic light therapy (PDT) in patients ... cancer that most often manifests itself in the lining ... exposure to asbestos. The grant will fund a clinical ...
(Date:7/9/2014)... of lung cancer, researchers have uncovered mutations in a ... The new knowledge may expand treatments for patients because ... available or are in clinical trials. , Reporting July ... Genome Atlas (TCGA), including researchers at Washington University School ... other institutions, studied tumors from 230 patients with lung ...
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... July 9, 2014 There has been a sharp ... Southwestern Medical Center using MyChart, the online, interactive service ... communicate with their healthcare providers, schedule appointments, and renew ... patients actively using MyChart each year increased ... increased more than 10-fold, according to a study by ...
Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3
... , LYNBROOK, N.Y., Sept. 16 ... a biopharmaceutical company developing first-in-class collagenase-based products, today announced ... Food and Drug Administration,s (FDA) unanimously recommended by a ... histolyticum), a novel, first-in-class, orphan-designated, biologic, be granted marketing ...
... published online today [Thursday] estimates nearly 45,000 annual deaths are ... two and a half times higher than an estimate from ... study, "Health Insurance and Mortality in U.S. Adults," appears in ... Public Health . The Harvard-based researchers found that uninsured, ...
... , SAN FRANCISCO, Sept. 21 Medithrive, Inc., ... its state of the art dispensary, offering patients a beautiful ... of medicinal marijuana products. , , ... 16th, in San Francisco, CA, has positioned itself as the ...
... post-menopausal women with early breast cancer to the drug exemestane ... keeping them on tamoxifen for five years improves the chance ... for at least the next six years. "These ... mid-way through the five-year tamoxifen treatment plan provides a clear ...
... CINCINNATICancer predisposition resulting from the presence of a ... researchers at the University of Cincinnati (UC) have ... risk for development of cancer in individuals harboring ... a result of environmental exposure. Peter Stambrook, PhD, ...
... NEW YORK, Sept. 21 In a bid ... online auction of the Ysio Digital Radiology System. As the ... N.Y., presented them a check for $285,309. , , ... , http://inr.mediaseed.tv/oneClip_C/?feed=hK4UKEtcAILqy08qpCX6wBwEMnTvqjZg , , ...
Cached Medicine News:Health News:FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytren's Disease 2Health News:FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytren's Disease 3Health News:45,000 excess deaths annually linked to lack of health insurance: Harvard study 2Health News:Switching early breast cancer patients to exemestane improves long-term survival 2Health News:Cancer predisposition from genetic variation shows strong gender bias 2
(Date:1/15/2014)... 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced ... Global Industry Analysis, Size, Share, Growth, Trends And Forecast, ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... patients in order to treat dental impairments, for tooth ...
(Date:1/15/2014)... AARP Foundation today announced it has established a relief ... cold weather that has gripped much of the nation. AARP ... so to support these emergency relief efforts AARP and AARP ... mean up to $500,000 in aid. The matching program will ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... 9, 2012 SciVerse Hub, SciVerse Applications, ... Sciences Recognized for Innovation and Achievement ... medical information products and services, today announced that it ... American Publishers Awards for Professional and Scholarly Excellence (the ...
... SAN DIEGO, Feb. 9, 2012  Volcano Corporation (NASDAQ: ... precision guided therapy tools designed to enhance the diagnosis ... announced it will report its operating results for the ... The company will hold a conference call ...
Cached Medicine Technology:Elsevier Honored With Six PROSE Awards 2Elsevier Honored With Six PROSE Awards 3Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast 2
... Tests are available in 14 configurations including ... using Microgenics Antibody Technology, the SureStep™ MDMA ... care immunoassay targeted to detect MDMA that ... MDEA but no cross-reactivity to any isomer ...
... Our most popular onsite test! QuickScreen™ ... the urine sample, and your choice of ... QuickScreen™ multi-panels offer total flexibility for your ... into the specimen and the built-in timer ...
... products, SEDIPLAST® is a completely closed ... protect laboratory personnel from the risk ... a uniquely designed erythrocyte sedimentation rate ... and convenience as well as reliable ...
... guaiac as a test for the presence of ... compounds present in guaiac to quinones, resulting in ... is present, the heme portion of the hemoglobin ... the release of oxygen from hydrogen peroxide which ...
Medicine Products: